Merrill Lynch Upgrades Affymax (AFFY) to Neutral
More News related to Upgrades
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Merrill Lynch upgrades Affymax (AFFY) from Underperform to Neutral.
Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions.
Stocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
